New Buy Recommendation for This Healthcare Giant

BMO Capital analyst Alex Arfaei reiterated a Buy rating on Merck & Company (NYSE: MRK) today and set a price target of $70. The company’s shares opened today at $64.90, close to its 52-week high of $65.72.

According to, Arfaei is a 4-star analyst with an average return of 4.7% and a 60.4% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Kindred Biosciences, Eli Lilly & Co, and Valeant Pharma.

Currently, the analyst consensus on Merck & Company is Moderate Buy and the average price target is $65, representing a 0.2% upside.

In a report issued on February 3, Credit Suisse also maintained a Buy rating on the stock with a $72 price target.

Merck & Company’s market cap is currently $181.3B and has a P/E ratio of 32.34. The company has a book value ratio of 4.1453.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Patricia Russo, a Director at MRK sold 5,000 shares for a total of $322,100.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.